Back to search

Institutional Repository of Vilnius University

Lokalaus priešvėžinio gydymo modeliavimas panaudojant in vitro sistemą, sudarytą iš prostatos vėžio ląstelių DU-145 ir anti-PD-L1 imunomoduliatoriaus atezolizumabo /

Abstract

dc:description

Atezolizumab is an anti-PD-L1 monoclonal antibody which targets immunosuppressive PD 1 and PD-L1 axis used by cancer cells to avoid the host immune system and is approved for treatment of several types of cancer. Despite its efficacy in some types of cancer, atezolizumab monotherapy shows limited capabilities in the treatment of prostate cancer. Soluble sPD-(L)1 factors and chemotherapy drugs might possibly dictate atezolizumab effectiveness and an outcome of prostate cancer treatment. The main aim of this thesis is to describe sPD-(L)1 and chemotherapy drugs impact on atezolizumab effectiveness. Goals of the thesis: to assess PD-L1 expression in the prostate cancer cell line DU-145, to evaluate membranous PD-L1 interaction with atezolizumab, to determine preoperative blood serum PD-(L)1 concentrations of prostate cancer patients, to evaluate sPD-(L)1 effect on atezolizumab binding to PD-L1, to assess chemotherapy drugs impact on atezolizumab effectiveness. The flow cytometry approach was used to evaluate atezolizumab binding to membranous PD L1. Atezolizumab binding was measured by fluorescence intensity of prostate cancer cell line DU-145 caused by anti-PD-L1 FITC bound to unoccupied PD-L1 ligands after the effect of soluble sPD-(L)1 or drugs used in chemotherapy. Results show that DU-145 cells are PD-L1 positive and atezolizumab in vitro effectively binds to membranous PD-L1. However, atezolizumab interaction with membranous PD-L1 is suppressed by soluble sPD-L1 and sPD-1 factors found in prostate cancer patient’s blood serum. Furthermore, membranous PD-L1 expression is activated by drugs used in chemotherapy but nonetheless the additional PD-L1 ligands are effectively blocked by atezolizumab. All in all, soluble sPD-(L)1 molecules and PD L1 expression induction chemotherapy drugs should be considered in local anti-cancer therapies based on PD-L1 inhibitors.

Degree

thesis:*
Grantor dc:publisher
Institutional Repository of Vilnius University
Year dc:date
2022

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Survila, Žilvinas,

Rights

dc:rights
Statement dc:rights
  • info:eu-repo/semantics/openAccess
Language dc:language
lit

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
Vilnius University
Base URL
epublications.vu.lt/oai
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Survila, Žilvinas,. Lokalaus priešvėžinio gydymo modeliavimas panaudojant in vitro sistemą, sudarytą iš prostatos vėžio ląstelių DU-145 ir anti-PD-L1 imunomoduliatoriaus atezolizumabo /. Institutional Repository of Vilnius University, 2022. https://repository.vu.lt/VU:ELABAETD192979087&prefLang=en_US